Ginsenoside Compound K: Insights into Recent Studies on Pharmacokinetics and Health-Promoting Activities
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sharma, A. | - |
dc.contributor.author | Lee, H.-J. | - |
dc.date.available | 2020-08-13T01:35:43Z | - |
dc.date.created | 2020-07-24 | - |
dc.date.issued | 2020-07 | - |
dc.identifier.issn | 2218-273X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/77453 | - |
dc.description.abstract | Ginseng (Panax ginseng) is an herb popular for its medicinal and health properties. Compound K (CK) is a secondary ginsenoside biotransformed from major ginsenosides. Compound K is more bioavailable and soluble than its parent ginsenosides and hence of immense importance. The review summarizes health-promoting in vitro and in vivo studies of CK between 2015 and 2020, including hepatoprotective, anti-inflammatory, anti-atherosclerosis, anti-diabetic, anti-cancer, neuroprotective, anti-aging/skin protective, and others. Clinical trial data are minimal and are primarily based on CK-rich fermented ginseng. Besides, numerous preclinical and clinical studies indicating the pharmacokinetic behavior of CK, its parent compound (Rb1), and processed ginseng extracts are also summarized. With the limited evidence available from animal and clinical studies, it can be stated that CK is safe and well-tolerated. However, lower water solubility, membrane permeability, and efflux significantly diminish the efficacy of CK and restrict its clinical application. We found that the use of nanocarriers and cyclodextrin for CK delivery could overcome these limitations as well as improve the health benefits associated with them. However, these derivatives have not been clinically evaluated, thus requiring a safety assessment for human therapy application. Future studies should be aimed at investigating clinical evidence of CK. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | Biomolecules | - |
dc.title | Ginsenoside Compound K: Insights into Recent Studies on Pharmacokinetics and Health-Promoting Activities | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000554183200001 | - |
dc.identifier.doi | 10.3390/biom10071028 | - |
dc.identifier.bibliographicCitation | Biomolecules, v.10, no.7 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85088043073 | - |
dc.citation.title | Biomolecules | - |
dc.citation.volume | 10 | - |
dc.citation.number | 7 | - |
dc.contributor.affiliatedAuthor | Sharma, A. | - |
dc.contributor.affiliatedAuthor | Lee, H.-J. | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | anti-cancer | - |
dc.subject.keywordAuthor | anti-diabetic | - |
dc.subject.keywordAuthor | anti-inflammation | - |
dc.subject.keywordAuthor | compound M1 | - |
dc.subject.keywordAuthor | ginseng | - |
dc.subject.keywordAuthor | hepatoprotective | - |
dc.subject.keywordAuthor | safety | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.